--(BUSINESS WIRE)--We are a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians. Our current efforts are primarily focused on the commercialization of ZEGERID® (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension for the treatment of upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). ZEGERID was developed by us based on our proprietary, immediate-release proton pump inhibitor (PPI) technology. In the U.S. prescription market, our commercial organization promotes our ZEGERID products to a targeted group of gastroenterologists and primary care physicians who accounted for writing prescriptions for approximately one-third of the $14 billion market for PPIs in 2007. To further leverage our proprietary PPI technology and diversify our sources of revenue, we have entered into strategic alliances with two global pharmaceutical companies.
